1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMelanoma Research Program Survivorship Research Award is sponsored by Dept. of the Army -- USAMRAA. This award addresses the underfunded area of melanoma-specific survivorship by supporting research aimed at improving the health and well-being of melanoma survivors, their families, and care partners.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DoD Melanoma, Team Science Award by Dept. of the Army -- USAMRAA | Atom Grants DoD Melanoma, Team Science Award This DoD grant funds multidisciplinary melanoma research projects led by multiple PIs, requiring pre-application invitation and aiming to improve patient outcomes. This grant is no longer accepting proposals Dept.
of the Army -- USAMRAA has archived this opportunity. Funder: Dept. of the Army -- USAMRAA Due Dates: June 30, 2025 (Pre-application) | October 1, 2025 (Full application, by invitation only) Funding Amounts: Up to $2.
1M total costs per team (combined across all PIs) for up to 3 years; ~7 awards expected; $14. 7M total program funding. Summary: Supports multidisciplinary, hypothesis-driven team projects advancing melanoma research or patient care, requiring 2–3 PIs and emphasizing collaboration across institutions or disciplines.
Key Information: Pre-application is required; only invited teams may submit a full application; clinical trials are not allowed. This opportunity funds collaborative, multidisciplinary research teams to advance the state of the science in melanoma research and/or patient care.
Projects must be hypothesis-driven and address at least one of the Melanoma Research Program (MRP) focus areas: prevention and interception, rare melanomas, or survivorship. The Team Science Award (TSA) mechanism is designed to bring together investigators from multiple disciplines and/or therapeutic areas to address complex, multi-dimensional problems in melanoma that cannot be solved by individual investigators working alone.
Distinctive features include: Requirement for 2–3 Principal Investigators (PIs) , each named on a separate award to their institution. Strong encouragement for multi-institutional partnerships . Projects must provide preliminary data supporting feasibility.
Inclusion of early-career, military, VA, and/or non-melanoma field investigators is encouraged. Engagement with the melanoma consumer community is encouraged but not required. Clinical trials are not permitted under this mechanism.
See the full grant listing
According to the current listing, eligibility includes: Unrestricted, subject to clarification in the text field entitled 'Additional Information on Eligibility'; the application must include at least one melanoma consumer collaborator, defined as a melanoma survivor, family…. Confirm the full requirements in the official notice before applying.
The current listing shows $2,040,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Melanoma Research Program Survivorship Research Award is funded by Dept. of the Army -- USAMRAA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article